Carlo Colosimo, MD, FEAN, Santa Maria University Hospital, Terni, Italy, discusses the development of movement disorders associated with oncological diseases and cancer immunotherapy, such as immune-checkpoint inhibitors (ICIs). Although ICIs have improved survivals and prognosis of several malignancies, in particular, melanoma and hematological malignancies, they may be responsible for the development of immune-related adverse events. ICIs can induce specific neurological adverse events, sometimes manifesting with movement disorders, both hypokinetic and hyperkinetic. Prof. Colosimo indicates that neurological adverse events are currently rare, but they may rise in the future due to the growing use of ICIs. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
